Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Mar 1;139(3):458-462.
doi: 10.1097/AOG.0000000000004674.

World Health Organization Recommendation for Using Uterine Balloon Tamponade to Treat Postpartum Hemorrhage

Affiliations

World Health Organization Recommendation for Using Uterine Balloon Tamponade to Treat Postpartum Hemorrhage

Andrew D Weeks et al. Obstet Gynecol. .

Abstract

The World Health Organization (WHO) recently published a new recommendation on the use of the uterine balloon tamponade for the treatment of postpartum hemorrhage. The recommendation that uterine balloon tamponade should be used only where there is already access to other postpartum hemorrhage treatments (including immediate recourse to surgery) has proved controversial. It is especially problematic for those working in low-level health care facilities in under-resourced settings, where there are already programs that have introduced low-cost uterine balloon tamponade devices for use, even in settings where recourse to surgical interventions is not possible. However, there are now two separate randomized trials that both unexpectedly show unfavorable outcomes in these settings when a condom catheter uterine balloon tamponade device was introduced. Considering the balance of potential benefits and these safety concerns, the WHO postpartum hemorrhage guideline panel therefore recommends that uterine balloon tamponade should be used only in contexts where other supportive postpartum hemorrhage interventions are available if needed.

PubMed Disclaimer

Conflict of interest statement

Financial Disclosure The authors did not report any potential conflicts of interest.

Similar articles

Cited by

References

    1. World Health Organization. WHO recommendation on uterine balloon tamponade for the treatment of postpartum haemorrhage. World Health Organization; 2021. - PubMed
    1. Anger HA, Dabash R, Durocher J, Hassanein N, Ononge S, Frye LJ, et al. The effectiveness and safety of introducing condom‐catheter uterine balloon tamponade for postpartum haemorrhage at secondary level hospitals in Uganda, Egypt and Senegal: a stepped wedge, cluster‐randomised trial. BJOG 2019;126:1612–21. doi: 10.1111/1471-0528.15903 - DOI - PMC - PubMed
    1. Dumont A, Bodin C, Hounkpatin B, Popowski T, Traore M, Perrin R, et al. Uterine balloon tamponade as an adjunct to misoprostol for the treatment of uncontrolled postpartum haemorrhage: a randomised controlled trial in Benin and Mali. BMJ Open 2017;7:e016590. doi: 10.1136/bmjopen-2017-016590 - DOI - PMC - PubMed
    1. Helping Mothers Survive. Bleeding after birth complete: preventing deaths from postpartum haemorrhage. Accessed October 31 2021. https://hms.jhpiego.org/bleeding-after-birth-complete/
    1. Adegoke O, Danso-Bamfo S, Sheehy M, Tarimo V, Burke TF, Garg LF. A condom uterine balloon device among referral facilities in Dar Es Salaam: an assessment of perceptions, barriers and facilitators one year after implementation. BMC Pregnancy Childbirth 2020;20:34. doi: 10.1186/s12884-020-2721-9 - DOI - PMC - PubMed

Publication types